{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"1.8","value":"1.7"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"2.7","value":"1.8"},{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG002","lowerLimit":"0.9","upperLimit":"NA","value":"1.7"},{"groupId":"OG003","lowerLimit":"1.8","upperLimit":"5.6","value":"3.7"},{"groupId":"OG004","lowerLimit":"1.7","upperLimit":"2.1","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"25"}],"units":"Participants"}],"description":"PFS as assessed by investigator per RECIST v1.1, was defined as time (in months) from date of first dose of study drug to date of first documentation of PD or death due to any cause or data censoring date, whichever occurred first. PD: \\>= 20% increase in sum of diameters of target lesions, taking as a reference smallest sum on study treatment (this included baseline sum if that was smallest on study treatment). The sum must also demonstrate absolute increase of \\>=5 mm, or appearance of \\>=1 new lesions. PFS was analyzed by Kaplan-Meier method. PFS data was censored on the date the last adequate tumor assessment for participants without an event (PD or death), for participants who started new anti-cancer treatment prior to PFS event, for participants with a PFS event after \\>=2 missing tumor assessments.","dispersionType":"95% Confidence Interval","groups":[{"description":"During Phase 1b participants received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"OG000","title":"Combination B Phase 1b: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 1.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"OG001","title":"Combination B Phase 1b: PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 3.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"OG002","title":"Combination B Phase 1b: PF-04518600 3.0 mg/kg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"OG003","title":"Combination B Phase 2 NSCLC: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 2 participants with SCCHN received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"OG004","title":"Combination B Phase 2 SCCHN: PF-04518600 0.3 mg/kg + Avelumab"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all enrolled participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug until first documentation of PD or death due to any cause or data censoring date, whichever occurred first (maximum up to 7.3 years)","title":"PFS for Combination B","type":"SECONDARY","unitOfMeasure":"Months"}